Cargando…

Update on the clinical utility of once-daily tacrolimus in the management of transplantation

Adherence to immunosuppression and minimizing variability in drug exposure are important considerations in preventing rejection and maximizing overall transplant outcomes. The availability of once-daily tacrolimus may confer potential benefit by simplifying immunosuppressive regimens, thereby improv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Posadas Salas, Maria Aurora, Srinivas, Titte R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155987/ https://www.ncbi.nlm.nih.gov/pubmed/25210441 http://dx.doi.org/10.2147/DDDT.S55458

Ejemplares similares

Update on the clinical utility of once-daily tacrolimus in the management of transplantation
por: Revollo, Jane
Publicado: (2015)

Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine
por: Kamel, Mahmoud, et al.
Publicado: (2016)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
por: Vadcharavivad, Somratai, et al.
Publicado: (2019)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Safety and Efficacy of Conversion from Twice-Daily Tacrolimus to Once-Daily Tacrolimus One Month after Transplantation: Randomized Controlled Trial in Adult Renal Transplantation
por: Oh, Chang-Kwon, et al.
Publicado: (2014)

Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study
por: Fernandez Rivera, Constantino, et al.
Publicado: (2021)

Mediastinal mass and pericardial tamponade in a renal transplant recipient: A rare case of nocardia infection
por: Salazar, Maria Nieva, et al.
Publicado: (2013)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients
por: Hurwitz, Jason T, et al.
Publicado: (2021)

Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
por: Gaber, A. Osama, et al.
Publicado: (2013)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
por: Kim, Jong Man, et al.
Publicado: (2020)

Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
por: Suh, Suk-Won, et al.
Publicado: (2016)

Correction to: Once-Daily versus Twice Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
por: Vadcharavivad, Somratai, et al.
Publicado: (2019)

Update on once-daily zonisamide monotherapy in partial seizures
por: Afra, Pegah, et al.
Publicado: (2014)

Intestinal Permeability in Patients Early after Kidney Transplantation Treated with Two Different Formulations of Once-Daily Tacrolimus
por: Kolonko, Aureliusz, et al.
Publicado: (2023)

The effect of Maintenance Treatment with Twice-daily or Prolonged Once-daily Tacrolimus Formulation on Visual Evoked Potentials in Stable Kidney Transplant Recipients
por: Kolonko, Aureliusz, et al.
Publicado: (2020)

A Case of BK Nephropathy without Detectable Viremia or Viruria
por: Kamel, Mahmoud, et al.
Publicado: (2015)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus
por: Guirado, Lluís, et al.
Publicado: (2015)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

Short- and Long-term Outcomes of De Novo Liver Transplant Patients Treated With Once-Daily Prolonged-Release Tacrolimus
por: Okumura, Yuichiro, et al.
Publicado: (2017)

Tacrolimus monotherapy in a patient with lupus flare using once-daily administration protocol
por: Tanaka, Hiroshi, et al.
Publicado: (2011)

Potentially serious medication errors with a new once-daily preparation of tacrolimus (Advagraf™)
por: Saif, Imran, et al.
Publicado: (2009)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation
por: Willuweit, Katharina, et al.
Publicado: (2020)

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial
por: Faravardeh, Arman, et al.
Publicado: (2021)

Therapeutic drug monitoring of modified release once daily tacrolimus in de novo renal transplant with conversion to a twice daily generic in the stable period
por: Mathew, Binu Susan, et al.
Publicado: (2015)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Clinical experience with once–daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1–year follow up
por: Ishida, Kenichiro, et al.
Publicado: (2013)

Tacrolimus for the management of psoriasis: clinical utility and place in therapy
por: Malecic, Nina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cbcs0n70ijc4f5rrm86bhh9v79